AFWM
SGMO

Abich Financial Wealth Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Abich Financial Wealth Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-418
Closed -$150 – 773
2024
Q2 		$150 Buy
+418
New +$226 ﹤0.01% 761

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Abich Financial Wealth Management's SGMO Position: Q3 2024 in Review

Abich Financial Wealth Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 418 shares — an estimated $150 sold.

Abich Financial Wealth Management first reported a position in SGMO in Q2 2024 and held it in 1 quarter. The position peaked at $150 in Q2 2024. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

  • Abich Financial Wealth Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • Abich Financial Wealth Management sold 418 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $150.
  • Abich Financial Wealth Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2024 and held it in 1 quarter.
  • Abich Financial Wealth Management's SANGAMO THERAPEUTICS INC position peaked at $150 in Q2 2024.
  • 103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on Abich Financial Wealth Management's 13F filing for Q3 2024, filed 25 Oct 2024.